CD33-CD45 相互作用揭示了与阿尔茨海默氏症易感性的机械联系
bioRxiv : the preprint server for biology
|August 6, 2025
概括
阿尔茨海默病的易感性与CD33基因有关. CD33抑制了CD45,损害了粉样β清除,并导致AD病理.
科学领域:
- 免疫学 免疫学 免疫学
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
背景情况:
- CD33基因是一种先天性免疫受体,与阿尔茨海默病 (AD) 风险有关.
- 一种特定的CD33变异 (rs3865444 CC) 改变了基因剪接,并增加了全长CD33表达,与保护性AA基因型形成鲜明对比.
研究的目的:
- 在AD的背景下研究CD33和CD45之间的相互作用.
- 阐明CD33-CD45相互作用对微质功能和AD病理学的功能后果.
主要方法:
- 通过免疫细胞特异性检测,确定CD45作为CD33结合伙伴.
- 在共同培养模型中评估粉样β的微质清除和神经元树突脊柱完整性.
- 在人类单细胞和脑组织中分析CD33-CD45相互作用频率.
主要成果:
- CD45被确定为CD33的依赖酸的结合伙伴,CD33抑制CD45酸酶活性.
- 过度表达CD33或CD45损失损害了微质粉样蛋白β清除,并导致树突性脊柱损失.
- 在患有AD风险变异的个体和AD患者中,无论基因型如何,都观察到CD33-CD45相互作用的增加.
- CD33和PTPRC (CD45) 之间的基因表达相互作用与AD诊断和病理负担相关.
结论:
- 建立了CD33和CD45之间的功能相互作用,有助于AD易感性.
- 通过CD33介导的CD45的抑制在微质功能和AD的发病过程中起着不利的作用.
- 这种相互作用凸显了系统性骨髓质功能障碍作为阿尔茨海默病的因素.
更多相关视频
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
11.9K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.1K
相关概念视频
Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
